Literature DB >> 26636884

Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.

Steven K Jones1, Vincent Lizzio2,3, Olivia M Merkel1,3.   

Abstract

This paper focuses on the ability of a folate-decorated triblock copolymer to deliver a targeted dose of siRNA in order to overcome chemotherapy resistance which can commonly cause complications in ovarian cancer patients. The micelleplexes that are formed upon electrostatic interaction with siRNA are used to deliver siRNA in a targeted manner to SKOV-3 ovarian cancer cells that overexpress folate receptor-α (FRα). The triblock copolymer consists of polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (PEI-g-PCL-b-PEG-Fol). In this work, polymers of different molecular weights of PEG, as well as different grafting degrees of the (g-PCL-b-PEG-Fol) chains to PEI, were analyzed to optimize targeted siRNA delivery. The polymers, their micelleplexes, and the in vitro performance of the latter were characterized by nuclear magnetic resonance, dynamic light scattering, transmission electron microscopy, flow cytrometry, western blot, confocal microscopy, and in luciferase assays. The different PEI-g-PCL-b-PEG-Fol conjugates showed suitable sizes below 260 nm, especially at N/P 5, which also allowed for full siRNA condensation. Furthermore, flow cytometry and Western blot analysis demonstrated that our best polymer was able to effectively deliver siRNA and that siRNA delivery resulted in efficient protein knockdown of toll-like receptor 4 (TLR4). Consequently, TLR4 knock down within SKOV-3 cells resensitized them toward paclitaxel (PTX) treatment, and apoptotic events increased. This study demonstrates that PEI-g-PCL-b-PEG-Fol conjugates are a reliable delivery system for siRNA and are able to mediate therapeutic protein knockdown within ovarian cancer cells. Additionally, this study provides further evidence to link TLR4 levels to chemotherapy resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26636884      PMCID: PMC4937801          DOI: 10.1021/acs.biomac.5b01189

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  48 in total

Review 1.  Engineering folate-drug conjugates to target cancer: from chemistry to clinic.

Authors:  Iontcho R Vlahov; Christopher P Leamon
Journal:  Bioconjug Chem       Date:  2012-06-26       Impact factor: 4.774

Review 2.  The development of site-specific drug delivery nanocarriers based on receptor mediation.

Authors:  Xueqing Wang; Suxin Li; Yujie Shi; Xingxing Chuan; Ji Li; Ting Zhong; Hua Zhang; Wenbing Dai; Bing He; Qiang Zhang
Journal:  J Control Release       Date:  2014-05-24       Impact factor: 9.776

3.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Authors:  Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

Review 4.  Folate-mediated delivery of macromolecular anticancer therapeutic agents.

Authors:  Yingjuan Lu; Philip S Low
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

5.  Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.

Authors:  A C Wang; Q B Su; F X Wu; X L Zhang; P S Liu
Journal:  Eur J Clin Invest       Date:  2009-02       Impact factor: 4.686

6.  Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.

Authors:  Susanne Markert; Silke Lassmann; Boris Gabriel; Maximilian Klar; Martin Werner; Gerald Gitsch; Felix Kratz; Annette Hasenburg
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

7.  Amphiphilic biodegradable PEG-PCL-PEI triblock copolymers for FRET-capable in vitro and in vivo delivery of siRNA and quantum dots.

Authors:  Thomas Endres; Mengyao Zheng; Ayşe Kılıç; Agnieszka Turowska; Moritz Beck-Broichsitter; Harald Renz; Olivia M Merkel; Thomas Kissel
Journal:  Mol Pharm       Date:  2014-03-12       Impact factor: 4.939

Review 8.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

9.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

10.  Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.

Authors:  Jin-Ming Li; Yuan-Yuan Wang; Wei Zhang; Hua Su; Liang-Nian Ji; Zong-Wan Mao
Journal:  Int J Nanomedicine       Date:  2013-06-05
View more
  22 in total

1.  Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.

Authors:  Tobias W M Keil; Daniel P Feldmann; Gabriella Costabile; Qian Zhong; Sandro da Rocha; Olivia M Merkel
Journal:  Eur J Pharm Biopharm       Date:  2019-08-21       Impact factor: 5.571

Review 2.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

3.  Revisiting the value of competition assays in folate receptor-mediated drug delivery.

Authors:  Steven K Jones; Anwesha Sarkar; Daniel P Feldmann; Peter Hoffmann; Olivia M Merkel
Journal:  Biomaterials       Date:  2017-05-22       Impact factor: 12.479

4.  Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.

Authors:  Daniel P Feldmann; Steven Jones; Kirk Douglas; Anthony F Shields; Olivia M Merkel
Journal:  Methods Mol Biol       Date:  2019

5.  Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles.

Authors:  Tobias Wm Keil; Christoph Zimmermann; Domizia Baldassi; Friederike Adams; Wolfgang Friess; Aditi Mehta; Olivia M Merkel
Journal:  Adv Ther (Weinh)       Date:  2021-05-07

Review 6.  RNA interference-based therapy and its delivery systems.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Xianchao Kong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

7.  FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.

Authors:  Esteban A Orellana; Srinivasarao Tenneti; Loganathan Rangasamy; L Tiffany Lyle; Philip S Low; Andrea L Kasinski
Journal:  Sci Transl Med       Date:  2017-08-02       Impact factor: 17.956

8.  Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.

Authors:  Steven K Jones; Kirk Douglas; Anthony F Shields; Olivia M Merkel
Journal:  Biomaterials       Date:  2018-06-13       Impact factor: 12.479

9.  The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking.

Authors:  Daniel P Feldmann; Yuran Xie; Steven K Jones; Dongyue Yu; Anna Moszczynska; Olivia M Merkel
Journal:  Nanotechnology       Date:  2017-05-10       Impact factor: 3.874

10.  Characterization of positively charged polyplexes by tunable resistive pulse sensing.

Authors:  Tobias W M Keil; Olivia M Merkel
Journal:  Eur J Pharm Biopharm       Date:  2020-12-15       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.